{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Anti-HAV",
        "LIAISON\u00ae XL Analyzer",
        "LIAISON\u00ae XL Workcell Upgrade Kit",
        "LIAISON\u00ae Control Anti-HAV"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K141116",
    "Predicate Device Reference 510(k) Number(s)": [
        "K103529"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOL",
        "JJF"
    ],
    "Summary Letter Date": "July 25, 2014",
    "Summary Letter Received Date": "April 30, 2014",
    "Submission Date": "April 29, 2014",
    "Regulation Number(s)": [
        "21 CFR 866.3310"
    ],
    "Regulation Name(s)": [
        "Hepatitis A virus (HAV) serological assays"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "Total antibodies to hepatitis A virus (Anti-HAV)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Sodium heparin plasma"
    ],
    "Specimen Container(s)": [
        "Primary tube",
        "Aliquot tube",
        "Pediatric tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer family",
        "LIAISON\u00ae XL Analyzer",
        "LIAISON\u00ae XL Workcell Upgrade Kit"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Automated immunoassay"
    ],
    "Methodologies": [
        "Serological testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Control",
        "Upgrade Kit"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae Anti-HAV assay and LIAISON\u00ae XL Analyzer with Workcell Upgrade Kit for qualitative detection of total antibodies to HAV using automated chemiluminescent immunoassay technology.",
    "Indications for Use Summary": "Qualitative detection of total antibodies to hepatitis A (anti-HAV) in human serum and sodium heparin plasma, used as an aid in laboratory diagnosis of current or past HAV infection and to determine antibody response in vaccine recipients.",
    "fda_folder": "Microbiology"
}